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ABSTRACT 
Antimalarial drug toxicity is viewed differently depending upon whether the clinical indication is for malaria treatment or prophylaxis. In the 
treatment of Plasmodium falciparum malaria, which has a high mortality if untreated, a greater risk of adverse reactions to antimalarial drugs is 
inevitable. Aschloroquine resistance has become widespread, alternative agents may be used in treatment regimens, however, the toxicity of 
these antimalarial agents should be considered.  Quinine is the mainstay for treating severe malaria due to itsrare cardiovascular or CNS 
toxicity, but its hypoglycemic effectmay be problematic. Mefloquine can cause dose-related serious neuropsychiatric toxicity and 
pyrimethamine dapsone is associated with agranulocytosis, especially if the recommended dose is exceeded. Pyrimethamine-sulfadoxinand 
amodiaquine are associated with a relatively high incidence of potentially fatal reactions, and are no longer recommended for prophylaxis. 
Atovaquone/proguanil is an antimalarial combination with good efficacy and tolerability as prophylaxis and for treatment. The artemisinin 
derivatives have remarkable efficacy and an excellent safety record. Prescribing in pregnancy is a particular problem for clinicians because the 
risk-benefit ratio is often very unclear. 
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Introduction 
Malaria, caused mostly by Plasmodium falciparum and P. 
vivax , remains one of the most important infectious diseases 
in the world. The current approaches to curtail this disease 
include vector control, vaccination, immunotherapy, malaria 
prevention during pregnancy and chemotherapy. The vector 
control is achieved by reducing vector density, interrupting 
their life cycle, and creating a barrier between the human 
host and mosquitoes.O ne of the most important current 
approaches to develop new drugs involves the synthesis of 
chemical libraries and their evaluation against most 
validated biochemical targets of malarial parasites. Avenues 
of research for the development of new antimalarial include 
lipid metabolism, degradation of hemoglobin and proteins, 
interaction with molecule transport, iron metabolism, 
apicoplasty, and signal transduction. Throughout the course 
of evolution, microorganisms have thwarted traps set by the 
environment including those designed by man. P. falciparum 
, which is responsible for causing severe forms of the disease, 
is also adept at developing resistancet o drugs thereby 
decreasing their efficacy in treatment over a period of time. 
Antimalarial drug toxicity is one side of the risk-benefit 
equation and is viewed differently depending upon whether 
the clinical indication for drug administration is malaria 
treatment or prophylaxis. Research that leads to drug 
registration tends to omit two important groups who are 
particularly vulnerable to malaria very young children and 
pregnant women. Prescribing in pregnancy is a particular 
problem for clinicians because the risk-benefit ratio is often 
very unclear[1]. In the prevention of malaria in travelers, a 
careful risk-benefit analysis is required to balance the risk of 
acquiring potentially serious malaria against the risk of harm 
from the prophylactic agent. The therapeutic ratios for some 
antimalarials are narrow, and toxicity is frequent when 
recommended treatment dosages are exceeded; parenteral 
administration above the recommended dose range is 
especially associated with the hazards of cardiac and 
neurological toxicity [2] . The purpose of this review is to 
update physicians on the toxicity associated with 
antimalarial drugs. The toxicity of antimalarial drugs sets an 
unusual and interesting problem for the clinician. Unlike 
most clinical situations, antimalarial drugs are provided to 
healthy people who are requesting treatment to provide 
extra security against ill health whilst travelling in malarial 
areas. Any significant degree of toxicity from these drugs 
Badhe et al                                                                                                              Journal of Drug Delivery & Therapeutics. 2019; 9(4):720-725 
 
ISSN: 2250-1177                                                                                   [721]                                                                                     CODEN (USA): JDDTAO 
undermines the whole logic behind the advice given to 
travellers. A risk-benefit assessment is necessary to decide 
between different regimens.[3]The toxicity of the drug must 
be balanced against the risk from malaria, as well as the 
efficacy of the drug. It has been estimated 
that travellers going on short (three week) trips to sub- 
Saharan Africa, who take some reasonable antimosquito 
precautions but take no chemoprophylaxis, have only a 1% 
chance of contracting clinical malaria. Clinical malaria has a 
mortality of no more than 1%if a policy of seeking medical 
advice or taking empiric antimalarial treatment for fevers is 
followed. Overall, 
the mortality of travellers who do not take 
chemoprophylaxisis therefore about 1 in 10000 trips'. 
Clearly, the risk to travellers going to endemic areasfor 
longer periods or shorter times will be correspondingly 
higher or lower; and travellers visiting areas of low 
endemicity will be at much lower risk. Decisions on 
chemoprophylaxis are normally based on the requirements 
of the typical traveller. From this, it is clear that any drug 
which has a frequency of fatal side-effects of 1 in 10 000, 
should not be used for routine prophylaxis. Furthermore, as 
non-toxic, though less effective, drugs are available, it is 
unlikely that drugs with a known frequency of fatal side-
effects of less than 1 in 40 000 should be considered for 
routine use. This theoretical view has been followed in 
practice whenever toxicity has been measured. In 
1985Fansidar was withdrawn as a recommended drug for 
routine prophylaxis on the basis of an estimated fatal 
adverse reaction rate of about 1 in 20000[4]. A year later 
amodiaquine was withdrawn because of an incidence of fatal 
neutropenia of about 1 in 20003.Unfortunately, there are few 
good techniques available to measure rates of severe adverse 
effects which are lower than 1 in 10 000. Prospective trials 
are not large enough to reliably detect side effects or adverse 
effects of such frequencies and the much lessre liable 
techniques of post-marketing surveillance must be used. This 
depends on using isolated case reports, reports to 
government agencies and to the pharmaceutical industry. 
These reports have to be assessed in the context of estimates 
of overall drug usage. Clearly, such estimates are very 
imprecise and drugs often have to be used for several years 
before even this imperfect information can be obtained. 
Incontrast, frequent but mild side effects are much easier to 
determine. Care is needed in interpreting the nature of mild 
side-effects because placebo controlled trials have shown 
that patients often suffer from non-specific side effects such 
as nausea, dizziness and headaches. In this review, I will 
attempt to summarise the main knowledge available on the 
incidence of major adverse effects and an outline of what is 
known about the minor side effects of the antimalarial drugs. 
Toxicity 
All drugs cause toxicity. Type A adverse effects (AEs)result 
from excessive responses to a drug; these AEs are 
predictable from the known effects of the drug and are dose 
or concentration related. In contrast, type B AEs aren ot 
predictable from the known effects of the drug; there may be 
an immunological basis to the AE, and there is often no clear 
relationship with the dose or concentration of drug. 
Furthermore, certain patient groups are at particular risk of 
severe AEs – including the elderly, the very young, glucose-6-
phosphate dehydrogenase (G6PD)-deficient people and HIV-
positive people – and these may not be well represented in 
submissions to regulatory authorities[5,6] . Toxicity may 
range from mild to serious and from reversible to 
irreversible [5] . Adequate clinical response is defined as rare 
toxicities, e.g. those which occur in ! 1% of patients using the 
agent, uncommon in1–10%, and common in 1 10%. 
Toxicity of Antimalarial Drugs 
All drugs used for malaria therapy or prophylaxis have 
common AEs, in addition to rare, mild to-severe and/or some 
times fatal AEs 
Chloroquine and Quinine [7] 
Chloroquine1 and quinine will be considered together as 
there are similarities in their toxic effects. Both drugs are 
quickly absorbed by the gastrointestinal tract and symptoms 
of poisoning usually appear within three hours of ingestion. 
The clinical features of poisoning include: 
• Drowsiness, convulsions and coma and 
• Hypotension and cardiac dysrhythmias 
(especially ventricular tachycardia and fibrillation)leading to 
cardiac arrest. Ventricular dysrhythmias may be anticipated 
from changes on the electrocardiogram (ECG): inversion of 
T-waves, prolongation of QT interval and widening of the 
QRS. 
• Respiratory failure. 
• Diplopia (double vision), blurred vision, 
narrowing(constriction) of the visual field (“tunnel” 
vision)and blindness. 
The toxic effects on the cardiovascular system tend to be 
more severe from chloroquine than quinine. Toxicity on the 
eye (oculotoxicity) is the major problem from quinine 
poisoning. 
The side effects of pharmacological treatment with quinine 
are common and become exaggerated when the patient has 
taken a toxic dose: 
• Nausea and vomiting, 
• Deafness and tinnitus, 
Vasodilatation (flushing sensation more obvious in a pale 
skin). This may be exacerbated by the vasodilatation caused 
by the malaria itself and so cause postural (orthostatic) 
hypotension. 
• Abdominal pain (especially epigastric) and 
• Visual impairment. 
• Hypoglycaemia may result from stimulation of the 
pancreatic islet beta-cells. This is more common in 
pregnancy and infants. The risk is reduced by administering 
the quinine with glucose. However the nursing and medical 
staff must be aware constantly of the probability of 
hypoglycaemia. 
• Thrombocytopenia may result from an immune mechanism 
associated with quinine but this is rarely of clinical 
importance. It may also be part of the disseminated 
intravascular coagulation syndrome. 
• Rashes and angio-oedemahave been described. Itching 
without a rash is a recognized problem affecting a number of 
Africans. 
• Confusional states also occur but distinguishing malaria 
and quinine as the underlying cause is difficult. 
• Black water fever (haemoglobinuria) is a serious 
complication. 
• Hypokalaemiais very common with chloroquine poisoning: 
even though a facility for serum potassium assay is absent 
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the hypokalaemia shouldbe assumed. The quantity of 
chloroquine ingested is a useful predictor of the likely 
symptoms and problems to expect[7] The ingestion of over 5 
grams of chloroquine and systolic hypotension (less than 
80mmHg) almost always 
lead to a fatal If the plasma concentration of quinine is less 
than 10mg/L the symptoms are usually mild but if greater 
than15mg/L the risk of permanent visual damage and 
cardiac dysrhythmias is high. 
Management of poisoning 
The priority is always to stabilize the poisoned patient with 
attention to the Airway, Breathing and Circulation. Ideally 
management should be carried out in an intensive care 
facility especially if the patient is shocked with hypotension. 
Adequate hydration should be established. 
Mechanical ventilation may be needed with the added 
support of very carefully titrated adrenaline [8]particularly if 
there is chloroquine poisoning. Adrenaline may increase the 
risk of cardiac dysrhythmias. If the ECG shows an 
intraventricular block then intravenous 250ml 8.4% sodium 
bicarbonate (i.e. 250mmol) is indicated. Gastric lavage 
should be considered if the patient arrives at the medical 
unit within one hour of ingesting quinine or chloroquine. If 
possible activated charcoal50 – 100G should then be given: 
this dose may need to be repeated every six hours depending 
on the clinicalresponse. There is no evidence that diazepam 
is cardiac protective. It is indicated for convulsions. 
Hypokalaemia may increase the risk of cardiac dysrhythmias. 
It might be tempting to give routinely an intravenous 
infusion of potassium. However during the recovery period 
severe “rebound” hyperkalaemia may develop. Therefore it is 
probably wise not to give extrapotassium unless frequent 
serum potassium measurements can be made and the results 
immediately available. 
'Safe' antimalarial drugs 
Chloroquine 
Chloroquine was first used in 1945 and since then hasbeen 
very widely employed throughout the world. During this 
time there have been few, if any, reports of severe or fatal 
adverse effects attributed to the use of the drug at the 
normal prophylactic dose; thus, it is reasonable to assume, in 
view of its huge consumption, that instances of fatal adverse 
effects to chloroquine are substantially less than 1 in a100 
000. This is equivalent to it being safe.[9] 
Non-fatal adverse events Chloroquine causes a shortterm 
and reversible effect on optical accommodationwhich can 
potentially affect eyesight during performanceof operators of 
high performance machineryor cars[10]. The true incidence 
of this effect has notbeen determined. Chloroquine binds 
irreversibly tomelanin and long term use of high dose 
dailychloroquine in patients with rheumatoid arthritismay 
lead to the accumulation of chloroquine in retina 
melanin[11]. There are only a few reports of retinopathy 
which have occurred in patients taking weekly chloroquine 
for malarial suppression[9]. In these cases the total dose of 
chloroquine has not been properly assessed. The experience 
of rheumatologists with higher (500 mg) daily doses of 
chloroquine suggests that retinopathy, lens and corneal 
changes can occur after total doses of 100 g5; experience 
with lower(250 mg) daily doses suggests that retinopathy 
does not occur until over 1000 g have been given. 
Hydroxychloroquine appears to be better tolerated than 
chloroquine[12] 
 
Proguanil 
Proguanil marketed in combination with atovaquoneis used 
for both the treatment of uncomplicated P. falciparumand 
prophylaxis of mild chloroquine-resistantmalaria. The most 
common AEs reported in 1 10% of patientstaking 
atovaquone/proguanil for treatment of malaria are 
abdominal pain, nausea, vomiting, and headachein adults, 
and vomiting in children; for prophylaxisof malaria AEs 
include headache and abdominal painand vomiting in 
children. It is well tolerated, and althoughoral aphthous 
ulcerations are not uncommon, they are rarely severe 
enough to warrant discontinuingthis medication. Proguanil is 
considered safe duringpregnancy and breastfeeding, but 
insufficient drug is excreted in the milk to protect a breastfed 
infant [13]. 
Non-fatal adverse events Since the dose of proguanilhas 
been increased to 200 mg there have been anincreasing 
number of reports of reversible aphthousulceration[14-17]. 
It is unclear what the incidence of this effect is, for it has 
varied from different reports;it is also unclear whether 
chloroquine taken incombination with proguanil aggravates 
and is responsiblefor the increasing incidence of this 
effectreported since 1986. 
Mefloquine 
Mefloquine is structurally similar to quinine. It isused for 
treatment or prophylaxis of drug resistant malaria.It may 
have cardiac depressant effects and antifibrillaryactivity, and 
may result in marked gastrointestinalor CNS AEs and is, 
therefore, not recommended asfirst-line treatment; nausea, 
strange dreams, seizures(rare), and psychosis may also occur 
[18] . Severe CNSevents requiring hospitalization (e.g. 
seizures and hallucinations)occur in 1: 10,000 patients 
taking mefloquineas chemoprophylaxis. However, milder 
CNS events (e.g.dizziness, headache, insomnia, and vivid 
dreams) aremore frequently observed, occurring in up to 
25% of patients.The higher incidence of AEs observed when 
thedrug is used at the higher doses needed for malaria 
treatmentimplies a dose effect [19] . It is contraindicated in 
hypersensitivity; epilepsy or seizure disorder; severe 
psychiatricdisorder, and in patients with a diagnosis or 
treatmentfor irregular heartbeat.Drugs with potential use 
aschemoprophylactic agents of unknown toxicity 
Doxycycline 
The tetracyclines have been in clinical use for many years 
and have been recently suggested as potential 
chemoprophylactic drugs. In one randomized study, minor 
adverse events were reported to be more common than with 
chloroquine alone: for instance, abdominal symptoms 
occurred in40% of patients compared with 15% in the 
chloroquine Group[20]. These suggestions have been made 
in the absence of reliable data on the incidence of fatal 
toxicity with this group of drugs. 
The theoretical risks are great: doxycycline can produce 
photosensitivity, allergic skin reactions, skeletal deposition 
with dental staining, oesophagitis, candida infections, 
pseudomembranous colitis, and perhaps enhancement of 
shigella and salmonella enteritis. The use of this drug in 
young children and in pregnancy is contraindicated because 
of discolouration of the teeth and possible adverse effects on 
development[20-23]. 
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Halofantrine 
Halofantrine has only been used much more recently and the 
numbers are not large enough to be able to detect the 
incidence of severe adverse events[24]. 
Antimalarial drugs withdrawn from use due to 
adverse effects 
Mepacrine 
Mepacrine was first used in 1935 and was widely employed 
throughout the Second World War. Severe cases of aplastic 
anaemia, transient psychotic reactions and exfoliative 
dermatitis have been described, together with more minor 
adverse events including yellow skin pigmentation and 
gastrointestinal disturbances. The incidence of adverse 
events is unknown. It is likely that the drug was withdrawn 
because of the high frequency of minor adverse events rather 
than the high frequency of life-threatening events. Also, at 
the time of withdrawal, the non-toxic drugs chloroquine and 
proguanil became widely available. 
Sulphonamides 
The use of sulphonamides was started in the1930s. The 
problems of severe skin reactions and neutropenia were well 
described. Neverthe less, a combination of pyrimethamine 
and sulfadoxine 
(Fansidar) was introduced in 1965. Twenty-two cases of 
Stevens-Johnson syndrome were observed with three deaths. 
In 1985, reports of severe skin reactions with six fatalities 
were reported in the United States2 and a corresponding 
number of nine cases (four fatal) in UK were also 
reported[25]. From an estimation of the frequency of the 
reported reactions and the number of tablets sold within the 
US, an incidence of fatal reactions of a frequency of1 in 18 to 
1 in 24 000 (with 95% confidence limits about 1 in 10-50 
000) has been reported[26]. It is unlikely that this toxicity is 
due to combination treatment as similar frequencies were 
observed in Beira when single doses of sulphadoxine were 
given to 150 000 people2. Examples of neutropenia have also 
been recorded with Fansidar, although the frequency of this 
has not been properly measured. Many studies suggest that 
this occurs approximately as frequently as severe skin 
reactions[27]. One dissenting Swiss study shows a much 
lower (1 in150000) incidence of severe adverse effects. 
Thereason for this difference remains obscure, although hit 
may simply reflect over-estimates of drug usage[28].It is 
unclear whether different formulations of sulphonamides 
have a significantly different incidence of severe adverse 
effects but, as these effects are so rare, it is unlikely that any 
high quality data will ever be produced that can be used to 
disprove this hypothesis. 
Dapsone 
Dapsone had been used since 1965 as prophylaxis against 
malaria and, ever since, its use has been associated with 
neutropenia. Originally, it was used in combination with 
chloroquine and primaquine at doses of 25 mg a day, and 
neutropenia occurred in 1 in 10 000 cases, 40% of which 
died[29]. Since then the combination of 12.5 mg 
pyrimethamine and 100 mg dapsone (Maloprim) at a dose of 
two tablets a week has been shown to be associated with 
agranulocytosis. A dose of one Maloprim tablet a day has also 
been associated with four cases of neutropenia, including 
two deaths1'. Dapsone is also associated with specific minor 
side-effects, in particular methaemoglobinaemia. The toxicity 
of low dose Maloprim (one a week) is still contentious as 
only a few reports of neutropenia have been associated with 
low dose use. Maloprim is not licensed in the US and is only 
used by a minority of travellers who are advised in Britain 
and Australia. Thus, in spite of the few cases reported, the 
frequency of fatal adverse effects is likely to lie in the grey 
area of 1 in 20 to 1 in 50 000, where the benefits of 
prophylaxis may not out weight the toxicity. 
Toxicity of Antimalarial Drugs 
Cardiovascular Toxicity 
Chloroquine has three main cardiovascular effects: 
membrane stabilization, direct negative inotropic effects, and 
direct arterial vasodilation. The data also suggest a role for 
nitric oxide and histamine release in mediating this response 
leading to hypotension/postural hypotension. 
These effects are manifested as rhythm and conductance 
disturbances, myocardiopathy, or vasoplegic shocks. Quinine 
and halofantrine are capable of prolonging the QT interval. 
Quinine prolongs the QT interval at standard doses, similar 
to halofantrine. Halofantrine induces a dose-related 
prolongation of the QT interval whereas mefloquine has no 
effect on the QT interval. However, the risk of significant QT 
prolongation was greater if halofantrine was given as a re-
treatment following mefloquine failure than as primary 
treatment. Cardiotoxicity of antimalarials is increased in 
patients with acute renal failure, especially after 3 days of 
treatment. This is partly because the degree of QT 
prolongation is dependent on the plasma concentration of 
halofantrine. The frequency of QT interval prolongations 
following artemether-lumefantrine treatment was similar to 
or lower than that observed with chloroquine, mefloquine, or 
artesunate +mefloquine; these changes were considerably 
less frequent than with quinine or halofantrine[30,31]. 
Ocular Toxicity 
Ocular toxicity caused by antimalarials was first described in 
the literature as early as 1957. As antimalarials were also 
found to be effective in the treatment of rheumatoid diseases 
apart from the treatment and prophylaxis of malaria, the risk 
of ocular toxicity is increased. The incidence of early 
retinopathy in ophthalmologically unmonitored patients was 
estimated by Bernstein [26] to be 10% for chloroquine and 
3–4% for hydroxychloroquine. Advanced retinopathy had an 
incidence of 0.5%. These risks might be reduced 
substantially by regular observation and testing [32]. The 
major toxicity of antimalarial agents is retinal damage (rare), 
which can lead to visual impairment. The major risk factor 
for retinal toxicity appears to be the combination of 
cumulative doses 800 g and age 70 years (presumably due to 
the increased prevalence of macular disease in the elderly). 
In the absence of risk factors, it is recommended that an 
ophthalmologic examination and central field testing be 
performed every 6–12 months. The central 10° of the visual 
field is the initial site of antimalarial retinal toxicity. There is 
a higher risk of visual loss when plasma concentrations of 
quinine exceed 15 mg/l at any stage of over dosage. Blurred 
vision may proceed to complete blindness within a few 
hours. As vision is lost, the pupils become dilated and 
unresponsive to light. Initially, only narrowing of the retinal 
arterioles may be seen on fundoscopy but after 3 days retinal 
edema may appear [33] . Hirstet al. reported that a 34-year-
old man treated with 1250 g of amodiaquine hydrochloride 
during 1 year was noted to have diffuse conjunctival and 
corneal changes and also demonstrated abnormal results in 
retinal function tests. 
Myopathy 
Factors increasing the risk of muscle disorders may depend 
on concomitant disease (diabetes, hypothyroidism, renal and 
hepatic disease), advanced age and dose. Myopathy has 
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rarely been reported with these agents. Clinicians should be 
aware that treatment may lead to neuromyopathy as well as 
irreversible retinopathy with chronic use. Usually patients 
complain of muscle weakness with or without muscle pain. 
Peripheral sensory abnormalities, such as lack of deep 
tendon reflexes, may be noted on examination. Muscle 
enzymes are normal or slightly elevated. In cases suspected 
of drug-induced myopathy, plasma concentrations of cellular 
contents released from damaged muscle are assessed. These 
laboratory parameters include creatine kinase, lactate 
dehydrogenase, aspartate aminotransferase, alanine 
aminotransferase, aldolase myoglobin, and potassium and 
phosphorus, both of which increase with muscle injury. 
Serum creatine kinase is considered to be the most sensitive 
indicator, but its lack of specificity is a major limitation. In 
the presence of drug-induced myopathy, serum creatine 
kinase may be normal, slightly elevated. 
Neurotoxicity 
Serial audiometry was performed in 10 patients receiving 
quinine treatment for acute P. falciparum malaria. Quinine 
reduced high-tone auditory responses. Tinnitus was 
reported in 7 patients after plasma concentrations 15 mg/ml, 
but the high-tone loss resolved completely after treatment 
was completed. Neuropsychiatric AEs of mefloquine range 
from anxiety and paranoia to depression, hallucinations, 
psychotic behavior andpossibly suicide [32] 
Hepatotoxicity 
Amodiaquine can cause AEs including liver damage. The 
observed drug toxicity is believed to involve the formation of 
an electrophilic metabolite, amodiaquine-quinoneimine, 
which can bind to cellular macromolecules and initiate 
hypersensitivity reactions. Since hepatitis and 
agranulocytosis occurred in prophylactically treated 
patients, it is no longer recommended as prophylactic 
treatment of malaria. Repeated exposure to the 
quinoneimine- generated antigen may be important in the 
generationof organ damage [35]. 
Pregnancy 
The US Centers for Disease Control and Prevention consider 
that chloroquine is safe throughout pregnancy, and 
mefloquine is safe in the second and third trimesters, with 
limited data suggesting safety in the first trimester [36]. 
Malaria often occurs in chloroquine-resistant regions, thus 
the pregnant traveler cannot generally choose chloroquine. 
Effectively, she has the choice of mefloquine in the second 
and third trimester, and nothing for the first trimester. The 
data suggest that mefloquine may lead to stillbirths if 
administered in the first trimester [37]. Published data on 
607 pregnancies in which artemisinin compounds were 
given during the 2nd or 3rd trimesters indicate no evidence 
of treatment-related, adverse pregnancy outcomes. Similar 
data show normal outcomes in 124 pregnancies exposed to 
artemisinin compounds in the 1st trimester. Artemisinin 
compounds cannot be recommended for treatment of 
malaria in the first trimester. Because the safety data are 
limited, artemisinin compounds should only be used in the 
second and third trimester. Artesunate-atovaquone-
proguanilis a well-tolerated, effective, practical, but 
expensive treatment for multidrug resistant P. falciparum 
malaria during the second or third trimester of pregnancy. 
Conclusions 
There are very little reliable data on the frequency of serious 
adverse effects with antimalarial drugs.Such data are very 
difficult to obtain and will never be available for newly 
marketed drugs. This means that great caution should be 
exercised before new drugs are recommended for 
widespread use by routine travellers who may have only a 
low (eg 1 to 10 000) risk of death from malaria without 
chemoprophylaxis. Furthermore, there is an urgent need for 
doctors to organize some morbidity assessment of the 
travelers that they have advised, on their return home, in 
order to provide accurate monitoring of the safety of 
currently recommended antimalarial regimens. 
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